Vivek Subbiah
Jeffrey and Christina Bird Professor and Professor of Pediatrics (Hematology/Oncology)
Medicine - Oncology
Clinical Focus
- Medical Oncology
Academic Appointments
-
Professor - University Medical Line, Medicine - Oncology
-
Professor - University Medical Line, Pediatrics - Hematology & Oncology
-
Member, Stanford Cancer Institute
Professional Education
-
Board Certification: American Board of Internal Medicine, Medical Oncology (2014)
-
Fellowship: UT MD Anderson Cancer Center Hematology and Oncology Fellowship (2012) TX
-
Fellowship: UT MD Anderson Cancer Center Hematology and Oncology Fellowship (2011) TX
-
Residency: Case Western Reserve University MetroHealth Internal Medicine Residency (2008) OH
-
Medical Education: Sri Ramachandra Institute of Higher Education (2002) India
https://orcid.org/0000-0002-6064-6837Clinical Trials
-
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Recruiting
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with other cancer treatments including monotherapy and in combination with other cancer treatments including immunotherapy or chemotherapy. This study is an open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in combination with pembrolizumab or other approved anticancer therapies or as a monotherapy in subjects with advanced unresectable, recurrent or metastatic tumors. The phase 1a (dose escalation phase) has been completed. The Phase 1b expansion phase of the study has been increased in size and scope.